Real-World Impact: Enhancing Prostate Cancer Diagnosis with AI

Watch the video to see how AI is driving diagnostic innovation at one of India’s leading cancer centers.

Singapore, July 3, 2024 — We are proud to share a real-world example of Qritive’s impact in clinical practice through our collaboration with the Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC) in India.

This video highlights how Qritive’s QAi Prostate Grade module has been successfully deployed to support pathologists at RGCIRC in improving the accuracy, consistency, and efficiency of prostate cancer diagnosis. The collaboration, facilitated by the MeitY–nasscom Center of Excellence, exemplifies the power of AI to advance patient care through scalable and clinically validated technology.

About Qritive

Qritive, headquartered in Singapore with operations in the US and India, is transforming digital pathology through advanced AI-powered solutions that support cancer diagnosis and improve health outcomes.

By leveraging cutting-edge deep learning technology, Qritive supports pathologists in the interpretation of pathology assessments and enhances pathology workflows—enabling faster, more accurate diagnoses and reducing time to treatment.

Qritive is committed to empowering healthcare professionals around the world with tools that promote collaboration and high performance, regardless of complexity or distance.

Get in Touch

Want to learn more about our solutions or explore potential collaborations?

Visit www.qritive.com or contact us at info@qritive.com.